Prasugrel treatment resulted in approximately 33% to 40% platelet inhibition as measured by both VerifyNow® P2Y12 and VASP, suggesting that patients with SCD achieved a substantial pharmacodynamic response with prasugrel treatment similar to that seen in previous studies in patients with cardiovascular disease. This evidence concerns the gene VASP and cardiovascular disorder.